myelosuppression

It has been developed as an oral tablet formulation for the treatment of TB in combination with bedaquiline and linezolid, two other anti-TB agents, and is now indicated for use inA a limited and specific population of patients.1A Adverse reactions reported during the Nix-TB trial of the BPaL regimen include hepatotoxicity, myelosuppression, as well as peripheral and optic neuropathy.A Please see additional safety information in the Important Safety Information below and in the accompanying pretomanid Full Prescribing Information.

Brincidofovir has a high barrier to resistance, no myelosuppression and a low risk of nephrotoxicity.

Consistent with prior studies, myelosuppression is the most common adverse event in both ongoing clinical trials.

Summary: The report features the unique and salient factors that are likely to significantly impact the development of the chemotherapy-induced myelosuppression treatment market during the forecast period.

Sprycel is associated with the following Warnings and Precautions: myelosuppression, bleeding-related events, fluid retention, cardiovascular events, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, embryo-fetal toxicity and effects on growth and development in pediatric patients.1Please see detailed Important Safety Information below.

Even though carboplatin is less toxic than other antineoplastic drugs, it still has severe adverse effects including myelosuppression and the marked release of free radicals (HUSAIN et al., 2001; WHEATE et al., 2010).

The product is being developed by the company as an adjuvant cancer therapy for the treatment of myelosuppression, induced by chemotherapy and radiotherapy.

Myelo001 is a new, clinical-stage adjuvant cancer therapy for the treatment of chemotherapy- and radiotherapy-induced myelosuppression. Preclinical and clinical studies have shown that Myelo001 applied orally is effective in reducing hematopoietic symptoms caused by chemotherapy and radiation.

Myelosuppression is the most important and dose-limiting toxicity of high-dose I-131 therapy but remains rare in clinical practice.

He said that he is using tofacitinib to treat a "handful" of alopecia patients who have been unresponsive to other treatments, are eager for an intervention that might regrow their hair, and who understand and accept the risk for developing an infection, shingles, or myelosuppression (with ruxolitinib treatment).